ProCE Banner Activity

All Eyes on ExPEC: A Major Driver of Invasive Disease and Antimicrobial Resistance

Video

Learn from experts about extraintestinal pathogenic Escherichia coli (ExPEC) concerns, populations at risk for invasive disease and approaches to ExPEC prevention, including an overview of the current landscape of vaccine development.

Released: November 03, 2022

Expiration: November 02, 2023

No longer available for credit.

Share

Faculty

Lilian Abbo

Lilian Abbo, MD, MBA, FIDSA

Professor of Infectious Diseases
Department of Medicine & Miami Transplant Institute
University of Miami Miller School of Medicine
Associate Chief Medical Officer in Infectious Diseases
Jackson Health System
Miami, Florida

Julie Ann Justo

Julie Ann Justo, PharmD, MS, FIDSA, BCPS

Clinical Pharmacist Lead – Infectious Diseases
Inpatient Pharmacy
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire

David Van Duin

David Van Duin, MD, PhD, FIDSA, FAST

Professor of Medicine
Director, Immunocompromised Host Infectious Diseases Program
Division of Infectious Diseases
University of North Carolina
Chapel Hill, North Carolina

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Janssen Therapeutics Division of Janssen Products

Program Director Disclosure

Program Director

Lilian Abbo, MD, MBA, FIDSA

Professor of Infectious Diseases
Department of Medicine & Miami Transplant Institute
University of Miami Miller School of Medicine
Associate Chief Medical Officer in Infectious Diseases
Jackson Health System
Miami, Florida

Lilian Abbo, MD, FIDSA: consultant/advisor/speaker: Ferring.

Faculty Disclosure

Primary Author

Julie Ann Justo, PharmD, MS, FIDSA, BCPS

Clinical Pharmacist Lead – Infectious Diseases
Inpatient Pharmacy
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire

Julie Ann Justo, PharmD, MS: consultant/advisor/speaker: bioMérieux, Entasis Therapeutics, Gilead Sciences, Merck, Shionogi, Spero Therapeutics, Therapeutic Research Center; individual publicly traded stock/stock options: Vaxart.

David Van Duin, MD, PhD, FIDSA, FAST

Professor of Medicine
Director, Immunocompromised Host Infectious Diseases Program
Division of Infectious Diseases
University of North Carolina
Chapel Hill, North Carolina

David Van Duin, MD, PhD, FIDSA, FAST: consultant/advisor/speaker: Entasis, Merck, Pfizer, Qpex, Roche, Shionogi, Union; researcher: Merck, Shionogi.

Staff Disclosure

Staff

Swathi K,

Editorial Contributor

Swathi.K, has no relevant financial relationships to disclose

Jacqueline Meredith, PharmD, BCIDP

Scientific Director

Jacqueline Meredith, PharmD, BCIDP, has no relevant financial relationships to disclose

Angeline Metilda, Mtech

Angeline Metilda, Mtech, has no relevant financial relationships to disclose

Quentin Minson, PharmD

Director of Educational Strategy

Quentin Minson, PharmD, BCPS, BCIDP, has no relevant financial relationships to disclose

Kristen Morrow, PhD

Editorial Contributor

Kristen Morrow, PhD, has no relevant financial relationships to disclose

Zachary Schwartz, MSc, ELS

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant financial relationships to disclose